| Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141) |
|---|
| 01/15/2002 | US6338848 Treating multiple sclerosis with immunoglobulins and interleukins |
| 01/15/2002 | US6338835 Radioprotectant for peptides labeled with radioisotope |
| 01/15/2002 | CA2030951C Process for producing immunostimulant agents |
| 01/10/2002 | WO2002002781A1 Heterodimeric fusion proteins |
| 01/10/2002 | WO2002002773A2 Dual specificity antibodies and methods of making and using |
| 01/10/2002 | WO2002002770A1 Novel g protein-coupled receptor protein and dna thereof |
| 01/10/2002 | WO2002002756A2 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 01/10/2002 | WO2002002751A2 Alteration of cell membrane |
| 01/10/2002 | WO2002002744A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 01/10/2002 | WO2002002645A1 COLD WATER SOLUBLE β-GLUCAN PRODUCT AND PROCESS FOR PREPARING THE SAME |
| 01/10/2002 | WO2002002641A1 Antibodies that immunospecifically bind to blys |
| 01/10/2002 | WO2002002640A2 Antibodies to human mcp-1 |
| 01/10/2002 | WO2002002638A2 Methods for treating rheumatic diseases using a soluble ctla4 molecule |
| 01/10/2002 | WO2002002634A2 Human extracellular matrix and cell adhesion polypeptides |
| 01/10/2002 | WO2002002633A2 Transporters and ion channels |
| 01/10/2002 | WO2002002619A1 The t-cell protein (tzon7), peptides and antibodies derived therefrom and uses thereof |
| 01/10/2002 | WO2002002610A2 Secretion and trafficking molecules |
| 01/10/2002 | WO2002002607A2 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | WO2002002603A2 Protein modification and maintenance molecules |
| 01/10/2002 | WO2002002587A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/10/2002 | WO2002002565A2 Glucocortiocoid-selective antiinflammatory agents |
| 01/10/2002 | WO2002002556A2 AZA-BRIDGED-BICYCLIC AMINO ACID DERIVATIVES AS α4 INTEGRIN ANTAGONISTS |
| 01/10/2002 | WO2002002551A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | WO2002002549A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/10/2002 | WO2002002542A1 Five-membered-ring compound |
| 01/10/2002 | WO2002002541A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002539A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | WO2002002525A2 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | WO2002002524A1 Pyrrole derivatives for treating aids |
| 01/10/2002 | WO2002002522A1 Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | WO2002002511A1 Substituted benzamides for immune enhancement and for the treatment of cancer, infection and manic-depressive illness |
| 01/10/2002 | WO2002002172A1 Dna palindrome - oligoguanylic acid compositions and uses thereof |
| 01/10/2002 | WO2002002141A2 Vaccine against helicobacter pylori |
| 01/10/2002 | WO2002002140A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 01/10/2002 | WO2002002139A2 Methods and composition for oral vaccination |
| 01/10/2002 | WO2002002132A1 Chemokine conjugates |
| 01/10/2002 | WO2002002131A2 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/10/2002 | WO2002002129A1 Use of grifola frondosa fungus extracts |
| 01/10/2002 | WO2002002109A1 Use of galiella lactone |
| 01/10/2002 | WO2002002090A2 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | WO2002002011A1 Dna encoding human serine protease d-g |
| 01/10/2002 | WO2001060404A3 Use of opri lipoprotein from pseudomonas as a th1 inducing natural adjuvant for heterologous antigens |
| 01/10/2002 | WO2001059071A3 Methods of preparing and using a viral vector library |
| 01/10/2002 | WO2001056993A3 Pyrazole compositions useful as inhibitors of erk |
| 01/10/2002 | WO2001056611B1 Oral delivery of allergens in milk |
| 01/10/2002 | WO2001045730A3 Tweak receptor |
| 01/10/2002 | WO2001043691A3 Fragments and antagonists of heat shock protein 60 |
| 01/10/2002 | WO2001042192A3 Vla-4 integrin antagonists |
| 01/10/2002 | WO2001036425A3 Imidazole compounds used as phosphodiesterase vii inhibitors |
| 01/10/2002 | WO2000066162A9 Mutant human cd80 and compositions for and methods of making and using the same |
| 01/10/2002 | WO2000055332A3 Human regulators of intracellular phosphorylation |
| 01/10/2002 | WO2000045800A3 Immunosurpressive effects of pteridine derivatives |
| 01/10/2002 | US20020004585 Antibody for use in the detection of preferential enzyme expression; for use as tool in treatment and detection of enzyme defects; for treatment autoimmune disease, inflammation, sepsis, diabetes, kidney defects and cancer |
| 01/10/2002 | US20020004584 HIV immune adjuvant therapy |
| 01/10/2002 | US20020004508 Novel carbocyclic nucleoside agents useful as selective inhibitors of proinflammatory cytokines |
| 01/10/2002 | US20020004238 Inducing immune response by administration of a recombinant protein; obtain cells, transform, propagate, inject into mammals, monitor immune response |
| 01/10/2002 | US20020004076 Oral immunology using plant product containing a non-enteric pathogen antigen |
| 01/10/2002 | US20020004044 Methods for inducing the differentiation of monocytes into functional dendritic cells |
| 01/10/2002 | US20020004041 Inducing tolerance in mammals to antigen via isolating peripheral blood mononuclear cells, then isolating dendritic cells and exposing to apoptotic cells in absence of cell surface glycoprotein receptors for HIV; prophylaxis |
| 01/10/2002 | DE10128980A1 Genetically modified T cells, useful e.g. for inhibiting allogenic transplant rejection, produced by incubating recipient and donor T cells then transducing with immunomodulatory gene |
| 01/10/2002 | CA2630062A1 Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| 01/10/2002 | CA2585012A1 Antibodies that immunospecifically bind to blys |
| 01/10/2002 | CA2415088A1 Aza-bridged-bicyclic amino acid derivatives as .alpha.4 integrin antagonists |
| 01/10/2002 | CA2415037A1 Glucocortiocoid-selective antiinflammatory agents |
| 01/10/2002 | CA2414807A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414799A1 Inhibitors of copper-containing amine oxidases |
| 01/10/2002 | CA2414660A1 Use of galiella lactone |
| 01/10/2002 | CA2414468A1 4-heteroaryl-3-heteroarylidenyl-2-indolinones and their use as protein kinase inhibitors |
| 01/10/2002 | CA2414464A1 Aryl phenycyclopropyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | CA2414461A1 Aryl phenylheterocyclyl sulfide derivatives and their use as cell adhesion-inhibiting anti-inflammatory and immune-suppressive agents |
| 01/10/2002 | CA2414375A1 Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis |
| 01/10/2002 | CA2414347A1 Vaccine comprising active agent immunogenic acyl glyceryl phosphatidylinositol manno-oligosaccharide |
| 01/10/2002 | CA2413756A1 Dna encoding human serine protease d-g |
| 01/10/2002 | CA2413245A1 N-ureidoheterocycloaklyl-piperidines as modulators of chemokine receptor activity |
| 01/10/2002 | CA2413237A1 Alteration of cell membrane for new functions |
| 01/10/2002 | CA2413186A1 Extracellular matrix and cell adhesion molecules |
| 01/10/2002 | CA2413166A1 Acid-modified arabinogalactan protein composition |
| 01/10/2002 | CA2413128A1 Transporters and ion channels |
| 01/10/2002 | CA2412872A1 Protein modification and maintenance molecules |
| 01/10/2002 | CA2412775A1 Antibodies to human mcp-1 |
| 01/10/2002 | CA2412287A1 Tetrahydropyridino or piperidino heterocyclic derivatives |
| 01/10/2002 | CA2412270A1 Pyrrole derivatives for treating aids |
| 01/10/2002 | CA2411692A1 Compositions and methods for the diagnosis and treatment of herpes simplex virus infection |
| 01/10/2002 | CA2410679A1 Secretion and trafficking molecules |
| 01/10/2002 | CA2410551A1 Heterodimeric fusion proteins |
| 01/10/2002 | CA2407910A1 Antibodies that immunospecifically bind to blys |
| 01/10/2002 | CA2406649A1 B7-like polynucleotides, polypeptides, and antibodies |
| 01/09/2002 | EP1170594A2 Methods for the identification of compounds useful for the treatment of disease states mediated by Prostaglandin D2 |
| 01/09/2002 | EP1170368A2 Immunization by inoculation of dna transcription unit |
| 01/09/2002 | EP1170017A1 Use of tumor necrosis factor alpha (TNF-alpha) and vascular endothelial growth factor (VEGF) for the manufacture of a therapeutic composition |
| 01/09/2002 | EP1170016A2 Urease-based vaccine against helicobacter infection |
| 01/09/2002 | EP1170015A1 Use of extracts of the fungus Grifola frondosa |
| 01/09/2002 | EP1170009A2 Thiazolybenzofuran derivatives and their use as SRS-A and leukotiene antagonists |
| 01/09/2002 | EP1169459A1 Dsp-9 dual-specificity map kinase phosphatase |
| 01/09/2002 | EP1169456A1 Recombinant toxin a/toxin b vaccine against clostridium difficile |
| 01/09/2002 | EP1169448A1 Tumor necrosis factor homologs and nucleic acids encoding the same |
| 01/09/2002 | EP1169445A2 Human proteins and polynucleotides encoding them |
| 01/09/2002 | EP1169442A2 Secreted and transmembrane polypeptides and nucleic acids encoding the same |
| 01/09/2002 | EP1169440A1 48 human secreted proteins |
| 01/09/2002 | EP1169353A1 Anti-idiotypic antibodies against antibodies which inhibit the binding of immunoglobuline to its high affinity receptor |